ALK and non-small cell lung carcinoma: Namely, two patients affected by NSCLC with EML4-ALK rearrangement treated with crizotinib orally 250 mg twice daily showed a remarkable improvement in their symptoms and prolonged objective responses during the dose-escalation phase.